Key result
Perceval size S sutureless valve links to ~1% 30-day mortality in small aortic annuli.
Why the study?
The treatment of aortic valve disease in small annuli remains debated regarding prosthetic choice and risk of patient prosthesis mismatch.
Observational (n=241)
Yes
Small size sutureless prostheses demonstrate good clinical outcomes and represent a viable alternative for patients with small aortic annuli who are at high risk for annular enlargement and anticoagulant therapy.
May support Perceval S consideration in high-risk small-annuli patients; extends observational data but leaves open need for RCTs.
BACKGROUND: The treatment of aortic valve disease in small annuli remains a debated topic in terms of prosthetic choice - biological or mechanical - and risk of patient prosthesis mismatch. METHODS: The clinical data of the 241 patients who received a small size sutureless prosthesis from the Sorin Universal REgistry on Aortic Valve Replacement (SURE-AVR) (NCT02679404) were analysed at 30 days and at follow-up. The mean age was 75.5 ± 7.8 years (89.2% female); the mean Society of Thoracic Surgeons (STS) score was 4.2 ± 3.2%, and the preoperative NYHA class II or III score was 83.8%. A minimally invasive approach was performed in 52.7% of patients; concomitant procedures were performed in 27.8% of patients. Similar aortic clamping and cardiopulmonary bypass times were observed in the overall isolated cohort and the isolated minimally invasive cohort. The mean intensive care unit (ICU) stay was 2.4 ± 2.0 days and the total length of stay was 10.3 ± 6.1 days. RESULTS: Three deaths were recorded at 30 days (1.2%), 2 for noncardiac causes. One patient experienced a myocardial infarction (0.4%) and 2 a nondisabling stroke (0.8%). 2 patients showed intraprosthetic leakage ≥ 2 and one patient para-prosthetic leakage ≥ 2; of these, one patient required reoperation with prosthesis removal. 4.1% of patients required a pacemaker implant. At a maximum follow-up of 8.1 years, 10 cardiovascular deaths, 4 valve related reinterventions (3 structural valve deterioration (SVD) requiring TAVI Valve-in-Valve, 1 endocarditis) occurred. CONCLUSIONS: With their good clinical outcomes, sutureless prostheses represent a good alternative for patients with small annuli, who are at high risk for annular enlargement and anticoagulant therapy. TRIAL REGISTRATION: Study number 587/2015.
No takes yet. Share an insight, caveat, or question.
Santarpino et al. (2025) conducted an observational in Aortic valve disease with small annuli (n=241). Perceval sutureless prosthesis (size S) was evaluated on 30-day mortality. The Perceval size S sutureless prosthesis demonstrated a 30-day mortality of 1.2% and a low rate of valve-related reinterventions (1.0% per patient-year) in patients with small aortic annuli.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: